Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for STRATA Skin Sciences (SSKN) over the last 13 years, with Q3 2025 value amounting to -$50000.0.

  • STRATA Skin Sciences' Asset Writedowns and Impairment changed N/A to -$50000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $175000.0, marking a year-over-year decrease of 2584.75%. This contributed to the annual value of $200000.0 for FY2024, which is 28181.82% up from last year.
  • Latest data reveals that STRATA Skin Sciences reported Asset Writedowns and Impairment of -$50000.0 as of Q3 2025.
  • STRATA Skin Sciences' 5-year Asset Writedowns and Impairment high stood at $141000.0 for Q1 2024, and its period low was -$95000.0 during Q1 2023.
  • In the last 5 years, STRATA Skin Sciences' Asset Writedowns and Impairment had a median value of $27000.0 in 2021 and averaged $18470.6.
  • The largest annual percentage gain for STRATA Skin Sciences' Asset Writedowns and Impairment in the last 5 years was 70000.0% (2021), contrasted with its biggest fall of 280000.0% (2021).
  • Quarter analysis of 5 years shows STRATA Skin Sciences' Asset Writedowns and Impairment stood at $27000.0 in 2021, then skyrocketed by 207.41% to $83000.0 in 2022, then grew by 14.46% to $95000.0 in 2023, then tumbled by 37.89% to $59000.0 in 2024, then tumbled by 184.75% to -$50000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$50000.0 for Q3 2025, versus $56000.0 for Q2 2025 and $110000.0 for Q1 2025.